HEPA - Pangali EV/EBITDA Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (HEPA) - logo korporat

This EV/EBITDA price chart for Hepion Pharmaceuticals (HEPA) demonstrates a metric of , while management optimizes clinical trial expenses to attract strategic partners. Hepion Pharmaceuticals (HEPA) is actively developing its portfolio of anti-fibrosis and NASH treatments, confirming the therapeutic value of its developments. The business leverages the massive potential of the anti-inflammatory market, creating solutions for individuals with chronic liver pathologies.

HEPA (Hepion Pharmaceuticals, Inc.) riwayat Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan saka 04.07.2022 nganti 15.11.2026

Rincian metrik komprehensif lan analitis Hepion Pharmaceuticals, Inc. (HEPA)

- rega pasar lan target rega analis:
Ringkesan analisis perusahaan:Hepion Pharma HEPA
Produk asli hepionpharma.com

High debt loads for capital-intensive companies create a risk of insolvency during sharp revenue declines. The diversification of Hepion Pharmaceuticals (HEPA) developments across several therapeutic areas mitigates these threats, providing a fundamental margin of safety. By analyzing the Enterprise Value to EBITDA ratio, an investor assesses the total business value relative to operating profit, determining the asset's real attractiveness while accounting for all liabilities.